10x Genomics, Inc. — Director's Dealing 2020

Dec 30, 2020

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2020-12-28

Reporting Person: CRUTCHFIELD BRADFORD (Chief Commercial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2020-12-28	Class A Common Stock	M	20312	$1.20	Acquired	21275	Direct
2020-12-28	Class A Common Stock	M	13333	$5.04	Acquired	34608	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2020-12-28	Stock Option (right to buy)	$1.20	M	20312	Disposed	2027-10-18	Class A Common Stock (20312)	Direct
2020-12-28	Stock Option (right to buy)	$5.04	M	13333	Disposed	2028-11-02	Class A Common Stock (13333)	Direct

Footnotes

F1: This option, originally for 25,000 shares, of which 20,312 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2017 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.

F2: This option, originally for 125,000 shares, of which 13,333 shares have been exercised, vested as to one forty-eighth of the shares on October 1, 2018 and one forty-eighth of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.